[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR9814040A - Agudo no pulmão com fibrose com antagonistas de avb6 - Google Patents

Agudo no pulmão com fibrose com antagonistas de avb6

Info

Publication number
BR9814040A
BR9814040A BR9814040-0A BR9814040A BR9814040A BR 9814040 A BR9814040 A BR 9814040A BR 9814040 A BR9814040 A BR 9814040A BR 9814040 A BR9814040 A BR 9814040A
Authority
BR
Brazil
Prior art keywords
fibrosis
antagonists
acute lung
avb6
treatment
Prior art date
Application number
BR9814040-0A
Other languages
English (en)
Inventor
Huang Xiaozhu
Sheppard Dean
Pytela Robert
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR9814040A publication Critical patent/BR9814040A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"TRATAMENTO DE FERIMENTO AGUDO NO PULMãO E FIBROSE COM ANTAGONISTAS DE <244>Vß6" Trata-se de métodos e composições que compreendem antagonistas de <244>vß6 para o tratamento de ferimento agudo no pulmão e fibrose.
BR9814040-0A 1997-08-08 1998-08-07 Agudo no pulmão com fibrose com antagonistas de avb6 BR9814040A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5506097P 1997-08-08 1997-08-08
PCT/US1998/016439 WO1999007405A1 (en) 1997-08-08 1998-08-07 TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF αvβ6

Publications (1)

Publication Number Publication Date
BR9814040A true BR9814040A (pt) 2000-10-03

Family

ID=21995323

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814040-0A BR9814040A (pt) 1997-08-08 1998-08-07 Agudo no pulmão com fibrose com antagonistas de avb6

Country Status (23)

Country Link
US (5) US20020004482A1 (pt)
EP (3) EP1504764B1 (pt)
JP (2) JP2001513333A (pt)
KR (1) KR100586202B1 (pt)
CN (1) CN1267224A (pt)
AT (3) ATE410179T1 (pt)
AU (1) AU739283B2 (pt)
BR (1) BR9814040A (pt)
CA (1) CA2297736A1 (pt)
CY (2) CY1110462T1 (pt)
CZ (1) CZ299768B6 (pt)
DE (2) DE69840113D1 (pt)
DK (2) DK1504764T3 (pt)
EE (1) EE04752B1 (pt)
ES (3) ES2235350T3 (pt)
HU (1) HU228900B1 (pt)
IL (2) IL134288A0 (pt)
NZ (2) NZ515955A (pt)
PL (2) PL199014B1 (pt)
PT (3) PT1930022E (pt)
RU (1) RU2221589C2 (pt)
TR (2) TR200202323T2 (pt)
WO (1) WO1999007405A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) * 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
CZ299768B6 (cs) * 1997-08-08 2008-11-19 The Regents Of The University Of California Farmaceutická kompozice pro lécení fibrózy ledvinnebo jater
DK1173201T3 (da) * 1999-04-22 2005-09-12 Biogen Idec Inc Fremgangsmåde til behandling af fibrose ved anvendelse af en antagonist af integrin-alfa-4-underenheden
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
US7320790B2 (en) * 2001-04-30 2008-01-22 Eli Lilly And Company Humanized antibodies
PL216223B1 (pl) 2002-03-13 2014-03-31 Biogen Idec Inc Przeciwciało przeciwko integrynom α<sub>v</sub>β<sub>6</sub>, jego fragment wiążący antygen, zawierająca je kompozycja i ich zastosowanie, komórka hybrydoma oraz sposób wykrywania α<sub>v</sub>β<sub>6</sub> in vitro
EP1492870A4 (en) * 2002-04-12 2005-08-03 Raven Biotechnologies Inc ANTIBODIES BINDING TO INTEGRIN-ALPHA-V-BETA-6 AND METHOD OF USE THEREOF
RS52918B (en) * 2004-04-02 2014-02-28 The Regents Of The University Of California PROCEDURES AND MIXTURES FOR TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH ALFA V BETA 5 INTEGRINE
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
US7927590B2 (en) 2006-07-10 2011-04-19 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
MX2009001293A (es) * 2006-08-03 2009-02-11 Astrazeneca Ab Anticuerpos dirigidos a (v(6 y usos de los mismos.
CA2665885A1 (en) * 2006-10-19 2008-12-04 The Regents Of The University Of California Treatment and prevention of chronic asthma using antagonists of integrin .alpha.nu.beta.6
AU2008299784B9 (en) 2007-08-02 2015-06-18 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
KR101046317B1 (ko) * 2008-07-04 2011-07-05 이종대 조력발전 방법 및 그 장치
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
JP5755647B2 (ja) 2009-07-24 2015-07-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア αｖβ５インテグリンに関連する疾患の処置および予防のための方法および組成物
NZ625850A (en) * 2009-08-21 2015-12-24 Gilead Biologics Inc Methods and compositions for treatment of pulmonary fibrotic disorders
BR112012008054A2 (pt) 2009-08-21 2017-05-23 Gilead Biologics Inc domínios catalíticos de lisil oxidase e loxl2
JP6134142B2 (ja) * 2010-02-04 2017-05-24 ギリアド バイオロジクス, インク.Gilead Biologics, Inc. リシルオキシダーゼ様２（ｌｏｘｌ２）に結合する抗体及びその使用方法
MX360141B (es) 2012-02-17 2018-10-24 Seattle Genetics Inc Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
EP2784511A1 (en) 2013-03-27 2014-10-01 Universität Zürich Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma
JP6104312B2 (ja) * 2014-06-19 2017-03-29 日東電工株式会社 組織再生促進剤
JP7034914B2 (ja) * 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
BR112020003498A2 (pt) 2017-08-22 2020-08-25 Biogen Ma, Inc. composições farmacêuticas e regimes de dosagem que contêm anticorpos anti-alfa(v)beta(6)
CA3159414A1 (en) 2019-12-05 2021-06-10 Seagen Inc. Anti-av.beta.6 antibodies and antibody-drug conjugates
WO2021225912A1 (en) * 2020-05-07 2021-11-11 Pliant Therapeutics, Inc. Treatment of respiratory diseases with amino acid compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
CA2006060A1 (en) 1988-12-20 1990-06-20 Michael D. Pierschbacher Polypeptide-polymer conjugates active in wound healing
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
DE69531187T2 (de) * 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
CZ299768B6 (cs) * 1997-08-08 2008-11-19 The Regents Of The University Of California Farmaceutická kompozice pro lécení fibrózy ledvinnebo jater

Also Published As

Publication number Publication date
RU2221589C2 (ru) 2004-01-20
PL341029A1 (en) 2001-03-26
EE200000068A (et) 2000-10-16
CN1267224A (zh) 2000-09-20
EP1930022B1 (en) 2011-06-08
WO1999007405A1 (en) 1999-02-18
EP0996460A1 (en) 2000-05-03
ATE511850T1 (de) 2011-06-15
NZ515955A (en) 2003-04-29
EP0996460A4 (en) 2001-03-07
JP2009001587A (ja) 2009-01-08
HU228900B1 (en) 2013-06-28
PT1504764E (pt) 2009-01-14
KR20010022740A (ko) 2001-03-26
US20070148173A1 (en) 2007-06-28
PT1930022E (pt) 2011-08-01
HUP0003547A2 (hu) 2001-02-28
CY1111792T1 (el) 2015-10-07
ES2311131T3 (es) 2009-02-01
EP1504764B1 (en) 2008-10-08
US20020004482A1 (en) 2002-01-10
AU739283B2 (en) 2001-10-11
EP0996460B1 (en) 2005-01-12
ATE410179T1 (de) 2008-10-15
EP1504764A1 (en) 2005-02-09
NZ502546A (en) 2002-02-01
ES2235350T3 (es) 2005-07-01
TR200202323T2 (tr) 2002-12-23
ES2364703T3 (es) 2011-09-12
DE69828614T2 (de) 2006-02-09
PL199014B1 (pl) 2008-08-29
KR100586202B1 (ko) 2006-06-07
AU8774398A (en) 1999-03-01
IL134288A0 (en) 2001-04-30
DK1504764T3 (da) 2008-11-17
US7544358B2 (en) 2009-06-09
JP2001513333A (ja) 2001-09-04
ATE286742T1 (de) 2005-01-15
US6692741B2 (en) 2004-02-17
TR200000374T2 (tr) 2000-09-21
CY1110462T1 (el) 2015-04-29
US20040208878A1 (en) 2004-10-21
EP1930022A1 (en) 2008-06-11
PL201716B1 (pl) 2009-05-29
IL134288A (en) 2008-07-08
DE69828614D1 (de) 2005-02-17
DE69840113D1 (de) 2008-11-20
DK1930022T3 (da) 2011-07-25
EE04752B1 (et) 2006-12-15
US6316601B1 (en) 2001-11-13
HUP0003547A3 (en) 2002-05-28
CZ299768B6 (cs) 2008-11-19
CZ2000413A3 (cs) 2000-11-15
US20010056076A1 (en) 2001-12-27
CA2297736A1 (en) 1999-02-18
US7150871B2 (en) 2006-12-19
PT996460E (pt) 2005-04-29

Similar Documents

Publication Publication Date Title
BR9814040A (pt) Agudo no pulmão com fibrose com antagonistas de avb6
EA199800667A1 (ru) Новые фенантридины
ID28846A (id) 2-fenilbenzimidazol dan 2_fenilindol, pembuatan dan penggunaanya
EE03741B1 (et) N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine
TR199801679T2 (xx) Osteoporoz i�in birle�tirme terapisi.
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
BR9706968A (pt) Uso de antagonistas de alfa-ppar e gama-ppar para o tratamento de sindrome x
BR9707609A (pt) Composição para desinfecção
DE69535450D1 (de) Pentafluorpropanzusammensetzungen
DE69905170T2 (de) Thiazolopyrimidinderivate
BR9505368A (pt) Composição cosmética ou dermatogógico água-em-óleo
DE59605572D1 (de) Synergistisches Stabilisatorgemisch
DE59611198D1 (de) Synergistisches Stabilisatorgemisch
ATE314387T1 (de) Dolastatin 15 derivate
DE59508533D1 (de) Synergistisches Stabilisatorgemisch
IT1285770B1 (it) Composti corticoidei
AR016981A2 (es) Polipeptidos sinteticos
EE04681B1 (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
DE69723576D1 (de) Die eierschalen von geflügel stärkende zusammensetzung
SE9802937D0 (sv) Novel compounds
EE9900524A (et) N-triasolüül-2-indoolkarboksamiidid ja nende kasutamine CCK-A agonistidena
PT1049706E (pt) Novos penta-sacaridos os respectivos metodos de producao e as composicoes farmaceuticas que os contem
NO992504D0 (no) Sammensetninger for behandling av jord, fremgangsmÕte for fremstilling derav, samt anvendelse
PT853959E (pt) Composicao para o tratamento do amianto
PT811593E (pt) Agentes insecticidas e acaricidas 1,4-diaril-2-fluor-2-buteno

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR. PORTANTO, INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO - DE ACORDO COM O ART. 8O DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]